364 related articles for article (PubMed ID: 16835321)
1. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.
Hiller T; Poppelreuther S; Stubenrauch F; Iftner T
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1262-7. PubMed ID: 16835321
[TBL] [Abstract][Full Text] [Related]
2. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
3. Isolation and functional analysis of five HPVE6 variants with respect to p53 degradation.
Hiller T; Stubenrauch F; Iftner T
J Med Virol; 2008 Mar; 80(3):478-83. PubMed ID: 18205217
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes.
Nees M; Geoghegan JM; Munson P; Prabhu V; Liu Y; Androphy E; Woodworth CD
Cancer Res; 2000 Aug; 60(15):4289-98. PubMed ID: 10945644
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells.
Pim D; Storey A; Thomas M; Massimi P; Banks L
Oncogene; 1994 Jul; 9(7):1869-76. PubMed ID: 8208532
[TBL] [Abstract][Full Text] [Related]
6. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
Hampson L; Kitchener HC; Hampson IN
Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826
[TBL] [Abstract][Full Text] [Related]
7. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes.
Asadurian Y; Kurilin H; Lichtig H; Jackman A; Gonen P; Tommasino M; Zehbe I; Sherman L
J Med Virol; 2007 Nov; 79(11):1751-60. PubMed ID: 17854024
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP.
Sherman L; Itzhaki H; Jackman A; Chen JJ; Koval D; Schlegel R
Virology; 2002 Jan; 292(2):309-20. PubMed ID: 11878933
[TBL] [Abstract][Full Text] [Related]
10. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
Pim D; Massimi P; Banks L
Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
[TBL] [Abstract][Full Text] [Related]
11. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells.
Chen TM; Chen CA; Hsieh CY; Chang DY; Chen YH; Defendi V
Oncogene; 1993 Jun; 8(6):1511-8. PubMed ID: 8389030
[TBL] [Abstract][Full Text] [Related]
12. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
[TBL] [Abstract][Full Text] [Related]
13. p53-independent abrogation of a postmitotic checkpoint contributes to human papillomavirus E6-induced polyploidy.
Liu Y; Heilman SA; Illanes D; Sluder G; Chen JJ
Cancer Res; 2007 Mar; 67(6):2603-10. PubMed ID: 17363579
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis.
Muench P; Probst S; Schuetz J; Leiprecht N; Busch M; Wesselborg S; Stubenrauch F; Iftner T
Cancer Res; 2010 Sep; 70(17):6913-24. PubMed ID: 20663910
[TBL] [Abstract][Full Text] [Related]
15. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential.
Elbel M; Carl S; Spaderna S; Iftner T
Virology; 1997 Dec; 239(1):132-49. PubMed ID: 9426453
[TBL] [Abstract][Full Text] [Related]
16. Telomerase activation by the E6 gene product of human papillomavirus type 16.
Klingelhutz AJ; Foster SA; McDougall JK
Nature; 1996 Mar; 380(6569):79-82. PubMed ID: 8598912
[TBL] [Abstract][Full Text] [Related]
17. Comparative transforming potential of different human papillomaviruses associated with non-melanoma skin cancer.
Massimi P; Thomas M; Bouvard V; Ruberto I; Campo MS; Tommasino M; Banks L
Virology; 2008 Feb; 371(2):374-9. PubMed ID: 17997466
[TBL] [Abstract][Full Text] [Related]
18. The role of TP53 in Cervical carcinogenesis.
Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
[TBL] [Abstract][Full Text] [Related]
19. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors.
Toussaint-Smith E; Donner DB; Roman A
Oncogene; 2004 Apr; 23(17):2988-95. PubMed ID: 14968115
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis.
Yuan H; Fu F; Zhuo J; Wang W; Nishitani J; An DS; Chen IS; Liu X
Oncogene; 2005 Jul; 24(32):5069-78. PubMed ID: 15856013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
